• 1
    Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971, 285: 11821186.
  • 2
    Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9: 653660.
  • 3
    Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52: 237268.
  • 4
    Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9: 677684.
  • 5
    Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: Progress and prospects. Hepatobiliary Pancreat Dis Int 2002, 1: 3541.
  • 6
    Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: Review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis 1997, 1: 2335.
  • 7
    Pandya NM, Dhalla NS, Santani DD. Angiogenesis --- a new target for future therapy. Vascul Pharmacol 2006, 44: 265274.
  • 8
    Yasumasa I, Izumi M, Yutaka T. Abietane type diterpenoids from Salvia miltiorrhiza. Phytochem 1989, 28: 31393141.
  • 9
    Zhi HB, Alfermann AW. Diterpenoid production in hairy root cultures of Salvia miltiorrhiza. Phytochem 1993, 32: 699702.
  • 10
    Mosaddik MA. In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine 2003, 10: 682685.
  • 11
    Choi HS, Kim KM. Tanshinones inhibit mast cell degranulation by interfering with IgE receptor-mediated tyrosine phosphorylation of PLCγ2 and MAPK. Planta Med 2004, 79: 178180.
  • 12
    Choi HS, Cho DI, Choi HK, Im SY, Ryu SY, Kim KM. Molecular mechanisms of inhibitory activities of tanshinones on lipopolysac-charide-induced nitric oxide generation in RAW 264.7 cells. Arch Pharm Res 2004, 27: 12331237.
  • 13
    Lee SY, Choi DY, Woo ER. Inhibition of osteoclast differentiation by tanshinones from the root of Salvia miltiorrhiza bunge. Arch Pharm Res 2005, 28: 909913.
  • 14
    Kang BY, Chung SW, Kim SH, Ryu SY, Kim TS. Inhibition of interleukin--12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 2000, 49: 355361.
  • 15
    Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E, Watanabe M et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 2007, 104: 39964001.
  • 16
    Roberts DD, Isenberg JS, Ridnour LA, Wink DA. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin Cancer Res 2007, 13: 795798.
  • 17
    Grobmyer SR, Kuo A, Orishimo M, Okada SS, Cines DB, Barnathan ES. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem 1993, 268: 1329113300.
  • 18
    He Q, Yang B, Lou YJ, Fang RY. Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo. Asian J Androl 2005, 7: 389393.
  • 19
    Lee MS, Moon EJ, Lee SW, Kim MS, Kim KW, Kim YJ. Angiogenic activity of pyruvic acid in vivo and in vitro angiogenesis models. Cancer Res 2001, 61: 32903293.
  • 20
    Zheng ZZ, Liu ZX. CD151 gene delivery increases eNOS activity and induces ECV304 migration, proliferation and tube formation. Acta Pharmacol Sin 2007, 28: 6672.
  • 21
    Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98: 428435.
  • 22
    Bian WP, Xu Y, Wang J, Chen F. The antiangiogenesis effect of cryptotanshinone on chick embryo chorioallantoic membrane. J Chinese Microcirculation 2007, 1: 2326.
  • 23
    Risau W. Mechanisms of angiogenesis. Nature 1997, 386: 671674.
  • 24
    Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc MP, Watier H. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007, 64: 210225.
  • 25
    Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 2003, 278: 3550135507.
  • 26
    Don MJ, Liao JF, Lin LY, Chiou WF. Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway. Br J Pharmacol 2007, 151: 638646.
  • 27
    Dittmann K, Gerhauser C, Klimo K, Hamburger M. HPLC-based activity profiling of Salvia miltiorrhiza for MAO A and iNOS inhibitory activities. Planta Med 2004, 70: 909913.
  • 28
    Dat NT, Jin X, Lee JH, Lee D, Hong YS, Lee K, Kim YH et al. Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. J Nat Prod 2007, 70:10931097.
  • 29
    Hur JM, Shim JS, Jung HJ, Kwon HJ. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Exp Mol Med 2005, 37: 133137.